Status:
TERMINATED
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Multiple Myeloma and Plasma Cell Neoplasm
Eligibility:
All Genders
18-120 years
Phase:
EARLY_PHASE1
Brief Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may...
Detailed Description
OBJECTIVES: * Determine the response rate in patients with recurrent multiple myeloma treated with recombinant interferon alfa and recombinant interleukin-6. * Determine the safety and optimal dose o...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of recurrent multiple myeloma
- Must have received ≥ 2 prior therapies
- PATIENT CHARACTERISTICS:
- Performance status 0-3
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00470093
Start Date
October 1 2007
End Date
January 1 2010
Last Update
November 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410